Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes

These results suggest that chemo-immunotherapy may be an effective strategy in genomically defined non-luminal subtypes of HR+/HER2- mBC following CDK4/6i resistance and highlight the value of molecular subtyping to guide post-endocrine treatment decisions.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-01-22
DOI
https://doi.org/10.1158/1078-0432.ccr-25-2570
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes

O. Castillo, Silvia Vázquez, Guillermo Villacampa, N. Chic et al.
Clinical Cancer Research
Advanced Breast Cancer Therapies
article

Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes

O. Castillo, Silvia Vázquez, Guillermo Villacampa, N. Chic, Cristina Hernándo, Manuel Alva, Lorea Villanueva, Paula Blasco, Sara Cano-Crespo, Fernando Salvador, Mafalda Oliveira, E Seguí, A. Prat, Salvador Blanch, Juan Antonio Virizuela, Adela Rodríguez Hernandez, B. Conte, Ana Vivancos, Esther Sanfeliu, Eva Ciruelos, Fara Brasó-Maristany, Patricia Galván, Juan Manuel. Ferrero-Cafiero, Tomás Pascual
article en

Abstract

These results suggest that chemo-immunotherapy may be an effective strategy in genomically defined non-luminal subtypes of HR+/HER2- mBC following CDK4/6i resistance and highlight the value of molecular subtyping to guide post-endocrine treatment decisions.

Clinical Cancer Research
Hebron University (PS), Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), Institut d'Investigació Biomédica de Bellvitge (ES), Hospital Universitario Virgen Macarena (ES), Hospital Clínico Universitario de Valencia (ES), Departament de Salut (ES), Hospital Universitario 12 De Octubre (ES), MedSIR (Spain) (ES), Vall d'Hebron Institut de Recerca (ES), Fundación Instituto Valenciano de Oncología (ES), Institut Català d'Oncologia (ES), Hospital Clínic de Barcelona (ES), Cancer Clinic (US), Vall d'Hebron Hospital Universitari (ES), Solti (ES), Oryzon Genomics (Spain) (ES), INCLIVA Health Research Institute (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Universitat de Barcelona (ES)
Openalex Percentile: Top 82%
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.